Autoimmune Conditions
Overview
Autoimmune conditions involve immune dysregulation where self-tolerance breaks down. Peptide therapy in this context focuses on restoring regulatory T-cell (Treg) function, reducing pathological inflammation, and supporting mucosal barriers. This is an area requiring careful clinical judgment — immune-stimulating peptides can worsen certain autoimmune conditions. Careful monitoring with autoimmune biomarkers (ANA, anti-dsDNA, inflammatory markers) is essential.
Recommended Peptides
- Thymosin Alpha-1 – induces Treg expansion via IDO (indoleamine 2,3-dioxygenase) pathway; most studied immunomodulatory peptide for autoimmune conditions; promotes immune tolerance rather than stimulation; used in clinical practice for conditions including lupus, MS, and rheumatoid arthritis
- KPV – anti-inflammatory alpha-MSH tripeptide; reduces inflammatory cytokines including IL-6, TNF-alpha, and IL-1beta; useful for gut-associated autoimmune conditions (IBD, celiac) and skin conditions (psoriasis)
- BPC-157 – reduces gut permeability (addressing the leaky gut-autoimmunity connection), modulates the inflammatory response, and has shown protective effects in animal models of inflammatory arthritis and colitis
Protocols
Related Conditions
Research Summary
Thymosin Alpha-1 provides dual immunomodulation — Th1 stimulation for pathogen defense and Treg induction via IDO pathway for immune tolerance (PMID-27450734). Safety confirmed across 11,000+ subjects (PMID-38308608). KPV inhibits NF-kB via PepT1-mediated intracellular uptake in colonic epithelium (PMID-18061177). BPC-157 stabilizes intestinal permeability relevant to autoimmune GI conditions (PMID-32445447).
Related
#condition #immune-system